title: The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.
abstract: FGFR1 amplification is recognized as a novel therapy target for non-small-cell lung cancer (NSCLC), especially in squamous cell carcinoma (SCC). However, the association between FGFR1 amplification and the clinicopathological characteristics of NSCLC remains controversial. We performed a meta-analysis of 17 eligible studies to examine the correlation between FGFR1 gene amplification and clinicopathological characteristics. FGFR1 amplification was closely related to these clinicopathological features, including sex (odds ratio [OR] 2.05, 95% confidence interval [CI] 1.50-2.80), smoking (OR 3.31, 95% CI 2.02-5.44), and histology (OR 3.60, 95% CI 2.82-4.59). FGFR1 amplification was associated with shorter overall survival, and no significant heterogeneity existed between studies (I (2)=3.8%). We should note that publication bias may partly account for these results, but our findings remained significant after the trim-and-fill method (hazard ratio 1.22, 95% CI 1.06-1.40). However, no significant correlation was found with poor disease-free survival (hazard ratio 1.43, 95% CI 0.96-2.12). In conclusion, this study showed that FGFR1 amplification was significantly associated with sex, smoking, and histology. FGFR1 amplification could be a marker of poor prognosis in NSCLC patients, especially in SCC patients.
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; Cancer Institute (Key Laboratory for Cancer Intervention and Prevention, China National Ministry of Education, Zhejiang Provincial Key Laboratory of Molecular Biology in Medical Sciences), Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
authors.forename: Fa-Jun
authors.initials: FJ
authors.lastname: Xie
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China.
authors.forename: Hong-Yang
authors.initials: HY
authors.lastname: Lu
authors.affiliation: Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China.
authors.forename: Qiu-Qing
authors.initials: QQ
authors.lastname: Zheng
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China.
authors.forename: Jing
authors.initials: J
authors.lastname: Qin
authors.affiliation: Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China.
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Zhang
authors.affiliation: Cancer Institute (Key Laboratory for Cancer Intervention and Prevention, China National Ministry of Education, Zhejiang Provincial Key Laboratory of Molecular Biology in Medical Sciences), Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
authors.forename: Xun
authors.initials: X
authors.lastname: Hu
authors.affiliation: Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou, People's Republic of China; Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Mao
keywords: FGFR1; amplification; meta-analysis; non-small-cell lung cancer